These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24646704)

  • 1. Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
    Isobe T; Komatsu R; Honda M; Kuramoto S; Shindoh H; Tabo M
    J Toxicol Sci; 2014 Apr; 39(2):237-42. PubMed ID: 24646704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
    Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR
    Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
    Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
    Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid development of hypertension by sorafenib: toxicity or target?
    Humphreys BD; Atkins MB
    Clin Cancer Res; 2009 Oct; 15(19):5947-9. PubMed ID: 19789317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
    Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
    Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
    PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
    Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
    Robinson ES; Khankin EV; Karumanchi SA; Humphreys BD
    Semin Nephrol; 2010 Nov; 30(6):591-601. PubMed ID: 21146124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
    Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
    Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Sorafenib and Bevacizumab on pancreatic volume - A monocentric CT based analysis.
    Phillip V; Zahel T; Bärtl K; Rasch S; Ebert O; Schmid RM; Rummeny E; Algül H
    Pancreatology; 2016; 16(4):621-4. PubMed ID: 26968257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
    Langenberg MH; van Herpen CM; De Bono J; Schellens JH; Unger C; Hoekman K; Blum HE; Fiedler W; Drevs J; Le Maulf F; Fielding A; Robertson J; Voest EE
    J Clin Oncol; 2009 Dec; 27(36):6152-9. PubMed ID: 19901116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
    Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
    Izzedine H; Mangier M; Ory V; Zhang SY; Sendeyo K; Bouachi K; Audard V; Péchoux C; Soria JC; Massard C; Bahleda R; Bourry E; Khayat D; Baumelou A; Lang P; Ollero M; Pawlak A; Sahali D
    Kidney Int; 2014 Feb; 85(2):457-70. PubMed ID: 24067439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hypertension in angiogenesis inhibitor-treated patients.
    Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
    Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
    BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
    Hamnvik OP; Choueiri TK; Turchin A; McKay RR; Goyal L; Davis M; Kaymakcalan MD; Williams JS
    Cancer; 2015 Jan; 121(2):311-9. PubMed ID: 25236375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.